[go: up one dir, main page]

MX2011009457A - Uso de lactoles de atorvastatina como medicamentos. - Google Patents

Uso de lactoles de atorvastatina como medicamentos.

Info

Publication number
MX2011009457A
MX2011009457A MX2011009457A MX2011009457A MX2011009457A MX 2011009457 A MX2011009457 A MX 2011009457A MX 2011009457 A MX2011009457 A MX 2011009457A MX 2011009457 A MX2011009457 A MX 2011009457A MX 2011009457 A MX2011009457 A MX 2011009457A
Authority
MX
Mexico
Prior art keywords
atorvastatin
lactols
medicaments
relates
analogues
Prior art date
Application number
MX2011009457A
Other languages
English (en)
Inventor
Peter Jackson
Derek Lindsay
Original Assignee
Redx Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redx Pharma Ltd filed Critical Redx Pharma Ltd
Publication of MX2011009457A publication Critical patent/MX2011009457A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se relaciona con el descubrimiento de análogos novedosos de atorvastatina; más específicamente, la invención se relaciona con análogos novedosos de atorvastatina que tienen utilidad en el tratamiento de condiciones tratables mediante la inhibición de HMG-CoA reductasa.
MX2011009457A 2009-03-10 2010-03-10 Uso de lactoles de atorvastatina como medicamentos. MX2011009457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904102.1A GB0904102D0 (en) 2009-03-10 2009-03-10 Use of atorvastatin lactols as medicaments
PCT/GB2010/050408 WO2010103319A1 (en) 2009-03-10 2010-03-10 Use of atorvastatin lactols as medicaments

Publications (1)

Publication Number Publication Date
MX2011009457A true MX2011009457A (es) 2012-04-10

Family

ID=40600803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009457A MX2011009457A (es) 2009-03-10 2010-03-10 Uso de lactoles de atorvastatina como medicamentos.

Country Status (19)

Country Link
US (1) US20110319626A1 (es)
EP (1) EP2405911B1 (es)
JP (1) JP5738205B2 (es)
KR (1) KR20110128193A (es)
CN (1) CN102387799B (es)
AU (1) AU2010222657B2 (es)
BR (1) BRPI1008942A2 (es)
CA (1) CA2754787A1 (es)
DK (1) DK2405911T3 (es)
EA (1) EA021034B1 (es)
ES (1) ES2411095T3 (es)
GB (1) GB0904102D0 (es)
IL (1) IL215038A (es)
MX (1) MX2011009457A (es)
NZ (1) NZ595110A (es)
PL (1) PL2405911T3 (es)
PT (1) PT2405911E (es)
WO (1) WO2010103319A1 (es)
ZA (1) ZA201107054B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0904104D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Atorvastatin and rosuvastatin derivatives
GB0904100D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0317393D0 (en) * 2003-07-25 2003-08-27 Avecia Ltd Process and compounds
KR101113163B1 (ko) * 2003-07-25 2012-02-17 브래드포드 파마 리미티드 스타틴, 특히 아토르바스타틴의 제조에 유용한 중간체화합물 및 그 제조방법
GB0406757D0 (en) * 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
DE102005022284A1 (de) * 2005-05-13 2006-11-23 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen
EP1834944A1 (en) * 2006-03-17 2007-09-19 Ratiopharm GmbH Process for preparing C7 intermediates and their use in the preparation on N-substituted pyrrole derivatives
GB0904104D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Atorvastatin and rosuvastatin derivatives
GB0904100D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments

Also Published As

Publication number Publication date
ES2411095T3 (es) 2013-07-04
EP2405911B1 (en) 2013-03-06
CA2754787A1 (en) 2010-09-16
PT2405911E (pt) 2013-06-05
CN102387799A (zh) 2012-03-21
WO2010103319A1 (en) 2010-09-16
IL215038A (en) 2014-06-30
AU2010222657B2 (en) 2014-10-02
DK2405911T3 (da) 2013-06-10
JP5738205B2 (ja) 2015-06-17
CN102387799B (zh) 2015-07-22
ZA201107054B (en) 2014-03-26
AU2010222657A1 (en) 2011-09-29
IL215038A0 (en) 2011-11-30
EP2405911A1 (en) 2012-01-18
JP2012520280A (ja) 2012-09-06
KR20110128193A (ko) 2011-11-28
EA021034B1 (ru) 2015-03-31
EA201101193A1 (ru) 2012-04-30
BRPI1008942A2 (pt) 2016-03-15
GB0904102D0 (en) 2009-04-22
US20110319626A1 (en) 2011-12-29
PL2405911T3 (pl) 2013-08-30
NZ595110A (en) 2013-02-22

Similar Documents

Publication Publication Date Title
GB0904100D0 (en) Use of rosuvastatin lactols as medicaments
JOP20180102A1 (ar) مركب صيدلاني
GEP20156266B (en) Spiroheterocyclic n-oxypiperidines as pesticides
CA2871471C (en) Dna-pk inhibitors
UA110197C2 (ru) Соединения, эффективные как ингибиторы для ксантиноксидазы, процесса получения таких соединений и фармацевтической композиции, содержащей терапевтически эффективное количество таких соединений.
IN2012DN03883A (es)
MY150596A (en) Hsp90 inhibitors
WO2011069063A3 (en) Multicyclic compounds and methods of use thereof
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MY160243A (en) Quinazolines as potassium ion channel inhibitors
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
MX2009005938A (es) 6-oxo-1,6-dihidro-pirimidin-2-ilos en el tratamiento de enfermedades proliferativas.
WO2011041311A3 (en) Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
WO2012017321A3 (en) Treatment for dyslipidemia
WO2011029536A3 (de) Verwendung von cyclischen ketoenolen gegen pflanzenpathogene bakterien
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
MX2011009458A (es) Derivados de rosuvastatina y atorvastatina.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
WO2010027458A3 (en) Pdk inhibitor compounds and methods of use thereof
MX2011009457A (es) Uso de lactoles de atorvastatina como medicamentos.
WO2009126335A3 (en) Ant2 inhibitor compounds and methods of use thereof
MX2012008253A (es) Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.

Legal Events

Date Code Title Description
FG Grant or registration